[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"growth-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:growth-failure":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100385104","targeted-fortification-of-donor-breast-milk-in-preterm-infants-100385104",false,"NCT04294368","Targeted Fortification of Donor Breast Milk in Preterm Infants","Inclusion Criteria:\n\n* Premature infants born \\\u003C\u002F= 30 weeks gestational age\n* Birth Weight \\\u003C\u002F= 1500 grams\n\nExclusion Criteria:\n\n* Parents do no consent to donor milk\n* Confounders for poor growth such as congenital heart disease, GI diagnoses such as gastroschisis and omphalocele, and or major congenital anomalies\n* Grade III or IV intraventricular hemorrhage diagnoses prior to randomization\n* Small for gestational age (\\\u003C3% on Fenton Growth Curve)\n* Failure to initiate fortified feeds prior to 3 weeks of life\n* Diagnosis of necrotizing entercolitis prior to randomization\n* Diagnosis of early onset sepsis confirmed with positive culture","ALL","1 Day","21 Days",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study is a randomized controlled trial comparing standard fortification of donor breast milk to targeted fortification of donor breast milk in preterm infants. The purpose of the study is to determine if there is a benefit to target fortifying donor breast milk in the preterm population. The investigators hypothesize that infants receiving targeted fortification of donor breast milk will have improved growth compared to infants receiving standard fortification of donor breast milk.",[26,27,28,29,30],"Prematurity; Extreme","Failure to Thrive in Newborn","Growth Retardation","Growth Failure","Infant Nutrition Disorders",[32,33,34,35,36],"Human Milk Analyzer","Miris","Target Fortification","Targeted Fortification","Donor Breast Milk","RECRUITING","2026-04-01",{"date":40,"type":41},"2026-04-07","ACTUAL",{"date":43,"type":41},"2020-03-09",{"date":45,"type":20},"2027-03",{"name":47,"class":48},"Columbia University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":15,"minAge":58,"maxAge":16,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100599314","impact-of-colostrum-oropharyngeal-immunotherapy-on-postnatal-growth-in-preterm-infants-100599314","NCT07082881","Impact of Colostrum Oropharyngeal Immunotherapy on Postnatal Growth in Preterm Infants","Impact of Colostrum Oropharyngeal Immunotherapy on Postnatal Growth in Preterm Infants Based on Early Gut Microbiota-Host Interaction Patterns: A Protocol for a Randomized Controlled Trial","IOCOIOPGIPI","Inclusion Criteria:\n\n1. Gestational age \\\u003C32 weeks and birth weight \\\u003C1500 g;\n2. admitted to the NICU of one of the five hospitals mentioned above within 24 h of birth; and\n3. able to initiate the protocol within 72 h of birth and continuously provide adequate colostrum until the end of the protocol.\n\nExclusion Criteria:\n\n1. Death within 48 h;\n2. severe birth asphyxia (defined as umbilical artery\u002Ffirst-hour arterial blood gas pH \\\u003C 7.0);\n3. birth with severe gastrointestinal malformations (e.g., intestinal atresia, tracheoesophageal fistula, malrotation of the intestines, and Hirschsprung's disease);\n4. prenatal diagnosis of congenital chromosomal abnormalities or suspected congenital genetic metabolic diseases; and\n5. maternal substance abuse or contraindications to breastfeeding (e.g., HIV).","0 Days",{"count":60,"type":20},220,[23],"The goal of this clinical trial is to ascertain whether oropharyngeal administration of colostrum contributes to postnatal growth in very preterm infants (those born before 32 weeks of gestation). The main questions it aims to answer are:\n\nCan Oropharyngeal administration of colostrum effectively lower the incidence rate of extrauterine growth restriction (EUGR) in participants? Does oropharyngeal colostrum intervention bring about changes in the early gut microbiota of participants? Researchers will conduct a comparative analysis between colostrum and a placebo (normal saline) to investigate whether oropharyngeal administration of colostrum has a beneficial effect on the postnatal growth of participants.\n\nParticipants will:\n\nInitiation of oropharyngeal colostrum administration will take place within 48 - 72 hours after birth, and the treatment will be administered continuously for a period of 5 days.\n\nStool samples will be collected from the participants both before and after the intervention.\n\nParticipants will be required to maintain a diary to document their basic characteristics and clinical outcomes.",[29,64,65],"Preterm Birth","Microbiota","NOT_YET_RECRUITING","2025-07-16",{"date":69,"type":41},"2025-07-24",{"date":71,"type":20},"2025-09-01",{"date":73,"type":20},"2028-09-30",{"name":75,"class":48},"Suqian First Hospital",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":15,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100448629","mal-ed-metabolic-a-follow-up-of-chronic-disease-at-puberty-100448629","NCT05121935","MAL-ED Metabolic: A Follow-Up of Chronic Disease at Puberty","Inclusion Criteria:\n\n* Participated in original MAL-ED cohort\n\nExclusion Criteria:\n\n* Did not participate in original MAL-ED cohort","9 Years","17 Years",{"count":85,"type":20},254,"OBSERVATIONAL","The concept that the roots of cardiometabolic disease start in early life was established by Dr. David Barker, who documented relationships between low birthweight (as a marker for challenges during gestation) and later cardiovascular disease (CVD). Later work has suggested that post-natal challenges (similar to prenatal ones) may also exhibit links to later cardiometabolic disease, with the strongest links appearing to be between low weight in early childhood and later hypertension and high waist circumference (WC). However, assessments for the relationship between early childhood challenges and insulin resistance and glucose regulation have been lacking and long-term cohort studies are few. In this project, we aim to assess children initially followed as part of The Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health (MAL-ED) study, where they received frequent measures of anthropometry and laboratory assessments for intestinal pathogens. These children are now of peri-pubertal age--a time period associated with metabolic shifts. We will assess for glucose dysregulation and findings associated with the metabolic syndrome, and we will analyze potential associations between current chronic disease risk findings with early life poor growth and intestinal pathogen carriage rate. As such, we hope to uncover potential targets in early life health to reduce later chronic disease risk.",[29,89,90,91],"Intestinal Infection","Metabolic Syndrome","Glucose Intolerance","2021-11-03",{"date":94,"type":41},"2021-11-16",{"date":96,"type":20},"2022-02-01",{"date":98,"type":20},"2031-02-01",{"name":100,"class":48},"University of Virginia"]